Immune Therapeutics, Inc. (OTCQB: IMUN) made two additions
to its board recently, and if experience and knowledge are said to be key
indicators of effectiveness, employees and shareholders alike have reason to be
elated with the news. Dr. Clifford A. Selsky and Paul Akin carry a wealth of
experience in their respective areas of influence and bolster the company’s
leadership assets going forward. Paul Akin brings financial experience
developed across his prior operating and board roles to the IMUN board. Dr.
Selsky offers a vital perspective as a scientist, physician and patient
advocate. The company intends to use their respective know-how on its road
toward pursuing financial growth while developing and commercializing novel,
patented therapies for life-threatening diseases by activating the body’s
immune system.
Noreen Griffin, CEO of Immune Therapeutics, noted in a press
release, “Paul Akin and Dr. Selsky’s breadth of knowledge and experience will
provide invaluable insight to Immune as we continue to grow the business and
strive to deliver innovative therapies in emerging nations.”
Clifford A. Selsky, PhD, MD, has been a pediatrician for the
past 20 years, earning his PhD in microbiology and molecular genetics at the
University of Miami School of Medicine prior to completing DNA repair research
studies at Harvard School of Public Health and Stanford University.
Paul Akin brings more than 25 years of leadership experience
to IMUN’s board. Akin played an important role in the strategic planning and
coordination of market penetration, capitalization and expansion. He currently
serves as the CEO and executive chairman of San Francisco-based Collier
Warehouse Group, where he’s fostered annual double-digit growth rates during
his tenure.
Immune Therapeutics, Inc. is a biotechnology company with a
leading portfolio of immunotherapy technologies aimed at capturing the promise
of the immune system for improving the treatment of cancer, HIV/Aids and other
chronic and autoimmune diseases. The company is currently looking into
investigations of its programs for met-enkephalin (MENK) and low dose
naltrexone (LDN), or Lodonal™ – as treatments for many underserved indications.
In February, leading independent equity research and
corporate access firm SeeThruEquity announced that it has initiated coverage on
Immune Therapeutics with a 12-month price target of $0.61.
Learn more by visiting www.immunetherapeutics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment